The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3029-3035

  Matsumoto, Fumihiko ^a,b   Valdecanas, David N ^a   Mason, Kathryn A ^a   Milas, Luka ^a   Ang, K Kian ^a   Raju, Uma ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR; FaDu cells; Head and neck cancer; IGF 1R; Radiation; Tumor response

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GANITUMAB; PANITUMUMAB; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; HEAD AND NECK CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; MICE; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865699798     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM and Roovers RC: Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 9: 748-760, 2009.
2. Morgillo F, Woo JK, Kim ES, Hong WK and Lee HY: Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib: Cancer Res 66: 10100-10111, 2006.
3. Ang KK, Andratschke NH and Milas L: Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58: 959-965, 2004.
4. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK and Kumar R: Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13: 4291-4299, 2007.
5. Ryott M, Wangsa D, Heselmeyer-Haddad K, Lindholm J, Elmberger G, Auer G, Avall Lundqvist E, Ried T and Munck-Wikland E: EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. Eur J Cancer 45: 1700-1708, 2009.
6. Liang K, Ang KK, Milas L, Hunter N and Fan Z: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57: 246-254, 2003.
7. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK and Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890, 1999.
8. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J and Fan Z: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708, 2000.
9. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
10. Bohula EA, Playford MP and Macaulay VM: Targeting the type 1 insulin-like growth factor receptor as anticancer treatment. Anticancer Drugs 14: 669-682, 2003.
11. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489, 2000.
12. Ozkan EE: Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review. Mol Cell Endocrinol 344: 1-24, 2011.
13. Hewish M, Chau I and Cunningham D: Insulin-like growth factor 1 receptor targeted therapeutics: Novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4: 54-72, 2009.
14. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R and Calzone FJ: AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 8: 1095-1105, 2009.
15. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R and Calzone FJ: Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 337: 644-654, 2011.
16. Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I and Murphy B: Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck 33: 1804-1808, 2010.
17. Cohenuram M and Saif MW: Panitumumab the first fully human monoclonal antibody: From the bench to the clinic. Anticancer Drugs 18: 7-15, 2007.
18. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ and Harari PM: Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 72: 534-542, 2008.
19. Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M and Ang KK: Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67: 568-572, 2007.
20. Blumenschein GR Jr., Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M and Sandler A: Phase Ib study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16: 279-290, 2010.
21. Casa AJ, Dearth RK, Litzenburger BC, Lee AV and Cui X: The type I insulin-like growth factor receptor pathway: A key player in cancer therapeutic resistance. Front Biosci 13: 3273-3287, 2008.
22. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002.
23. Riesterer O, Yang Q, Raju U, Torres M, Molkentine D, Patel N, Valdecanas D, Milas L and Ang KK: Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int J Radiat Oncol Biol Phys 79: 1179-1187, 2011.
24. Iwasa T, Okamoto I, Suzuki M, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K: Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 15: 5117-5125, 2009.
25. Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ and Harari PM: Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67: 1155-1162, 2007.
26. Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD and Boothman DA: Delayed activation of insulin-like growth factor-1 receptor/SRC/MAPK/EGR-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280: 14212-14221, 2005.
27. Lee HC, An S, Lee H, Woo SH, Jin HO, Seo SK, Choe TB, Yoo DH, Lee SJ, Hong YJ, Park MJ, Rhee CH, Park IC and Hong SI: Activation of epidermal growth factor receptor and its downstream signaling pathway by nitric oxide in response to ionizing radiation. Mol Cancer Res 6: 996-1002, 2008.
28. Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, Einama T, Morita D, Fukatsu K, Sugiura Y, Matsubara O and Mochizuki H: Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 19: 788-796, 2006.
29. Jin Q and Esteva FJ: Cross-talk between the ERBB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13: 485-498, 2008.
30. Rozengurt E, Sinnett-Smith J and Kisfalvi K: Crosstalk between insulin/insulin-like growth factor-1 receptors and G-protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16: 2505-2511, 2010.
31. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams, S, Wakeling AE and Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793-814, 2004.
32. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L and Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280: 19665-19672, 2005.
33. Lammering G, Valerie K, Lin PS, Hewit TH and Schmidt-Ullrich RK: Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72: 267-73, 2004.
34. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK and Chen PB: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15: 1191-1197, 1997.